CXCL13血浆水平可作为慢性淋巴细胞白血病疾病活动度的生物标志物
该研究分析了400例慢性淋巴细胞白血病(CLL)患者的血浆CXCL13浓度,并与其他预后标志物、至治疗时间(TTT)、CCL3/CCL4水平及体内CLL细胞增殖相关。发现活动期和晚期患者CXCL13较高且TTT显著缩短,高CXCL13与疾病活动标志物及CCL3水平相关,体内CLL细胞出生率较高也与CXCL13较高相关。伊布替尼治疗中升高的CXCL13可正常化,耐药患者则再次升高。
要点
- 血浆CXCL13在活动期和晚期CLL患者中升高,与更短至治疗时间相关。
- CXCL13与CCL3及体内CLL细胞出生率等疾病活动标志物相关。
- 伊布替尼治疗可使升高的CXCL13正常化,耐药时再次升高。
核心结论
- CXCL13血浆浓度与CLL疾病活动度和进展相关,可能作为疾病活动度的生物标志物。
研究设计与样本
- 研究分析了400例CLL患者的血浆CXCL13浓度,并与预后标志物、至治疗时间、CCL3和CCL4血浆浓度及体内CLL细胞增殖进行相关性分析。
主要发现
- 活动期和晚期CLL患者的CXCL13血浆浓度较高,至治疗时间显著缩短。
- 高CXCL13水平与其他疾病活动标志物及CCL3水平相关。
- 体内CLL细胞出生率较高与CXCL13血浆浓度较高相关。
- 伊布替尼治疗期间升高的CXCL13血浆水平正常化,在伊布替尼耐药患者中则升高。
临床怎么用
- CXCL13血浆水平有望辅助评估CLL疾病活动度和治疗反应,尤其在伊布替尼治疗监测中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The chemoattractant CXCL13 organizes the cellular architecture of B-cell follicles and germinal centers. During adaptive immune responses, CXCL13 plasma concentrations transiently increase and function as a biomarker for normal germinal center activity. Chronic lymphocytic leukemia (CLL) cells express high levels of CXCR5, the receptor for CXCL13, and proliferate in pseudofollicles within secondary lymphoid organs (SLO). Given the morphologic and functional similarities between normal and CLL B-cell expansion in SLO, we hypothesized that CXCL13 plasma concentrations would correlate with CLL disease activity and progression. We analyzed CXCL13 plasma concentrations in 400 CLL patients and correlated the findings with other prognostic markers, time to treatment (TTT), CCL3 and CCL4 plasma concentrations, and in vivo CLL cell proliferation. We found that CXCL13 plasma concentrations were higher in CLL patients with active and advanced stage disease, resulting in a significantly shorter TTT. Accordingly, high CXCL13 levels correlated with other markers of disease activity and CCL3 levels. Higher CLL cell birth rates in vivo also associated with higher CXCL13 plasma concentrations. Interestingly, elevated CXCL13 plasma levels normalized during ibrutinib therapy, and increased in ibrutinib resistance patients. Collectively, these studies emphasize the importance of CXCL13 in crosstalk between CLL cells and the SLO microenvironment.
引用
- Sivina M, Xiao L, Kim E, et al. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia. 2020. PMID: 33087831. doi:10.1038/s41375-020-01063-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。